GCP
CERE

GSA Capital Partners’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

GSA Capital Partners’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,607
Closed -$577K – 2056
2023
Q4 		$577K Buy
+13,607
New +$391K 0.05% 702
2021
Q4 		– Sell
-25,942
Closed -$765K – 1887
2021
Q3 		$765K Buy
+25,942
New +$728K 0.08% 444

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

GSA Capital Partners's CERE Position: Q1 2024 in Review

GSA Capital Partners sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 13,607 shares — an estimated $577K sold.

GSA Capital Partners first reported a position in CERE in Q3 2021 and held it in 2 quarters. The position peaked at $765K in Q3 2021. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

  • GSA Capital Partners reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • GSA Capital Partners sold 13,607 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $577K.
  • GSA Capital Partners first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • GSA Capital Partners's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $765K in Q3 2021.
  • 210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on GSA Capital Partners's 13F filing for Q1 2024, filed 3 May 2024.